"One pill, once daily": What clinicians need to know about Atripla™

Therapeutics and Clinical Risk Management

Volumn 4, Issue 2, 2008, Pages 291-302

  Clay, Patrick G ^a   Taylor, Tracey A H ^a   Glaros, Alan G ^a   McRae, Mary Peace ^a   Williams, Charlott ^a   McCandless, Don ^a   Oelklaus, Maurice ^a  

^a KANSAS CITY UNIVERSITY OF MEDICINE AND BIOSCIENCES   (United States)

Author keywords

Antiretrovirals; Atripla ; HIV

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MIDAZOLAM; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; TRIAZOLAM; VORICONAZOLE; ZIDOVUDINE;

ABDOMINAL PAIN; ALLERGIC REACTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANXIETY; AREA UNDER THE CURVE; ARTHRALGIA; BACKACHE; BONE DENSITY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; DYSPEPSIA; ETHNIC DIFFERENCE; EVENING DOSAGE; FATIGUE; FEVER; FOOD DRUG INTERACTION; GENETIC VARIABILITY; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LYMPHOBLASTOID CELL; MACULOPAPULAR RASH; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PNEUMONIA; POSTMARKETING SURVEILLANCE; PREGNANCY; RASH; RECOMMENDED DRUG DOSE; REVIEW; RHINITIS; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; URTICARIA; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 44049093717     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Abramowicz M, ed. 2006a. A once-daily combination tablet (Atripla) for HIV. Med Letter, 48:78-80.
2. Abramowicz M, ed. 2006b. Treatment guidelines from the Medical Letter: Drugs for HIV infection. Med Letter, 50:67-76.
3. Ammassari A, Trotta MP, Murri R, AdICoNA Study Group. 2002. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immun Defic Syndr, 31(Suppl 3):S123-7.
4. Arribas JR, Pozniak AL, Gallant JE, et al. 2007a. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/ lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr, Oct 25 [Epub ahead of print].
5. Arribas J, Pozniak A, Gallant J, et al. 2007b. Three-year safety and efficacy of emtricitabine (FTC)/tenofovir DF (TDF) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral treatment-naive patients. Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. July 22-25, 2007. Sydney, Australia. Abstract WEPEB029.
6. Atripla™ Package Insert. 2006. Bristol-MyersSquibb and Gilead Sciences, LLC. Foster City, California, US. July 2006.
7. Badri SM, Adeyemi OM, Max BE, et al. 2007. Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure. AIDS Patient Care STDS, 21:544-50.
8. Barrett JS, Joshi AS, Chai M, et al. 2002. Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther, 40:507-19.
9. Bartlett JA, Path MJ, Demasi R, et al. 2006. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS, 20:2051-64.
10. Bartlett JG, Lane CL, eds. 2007. US DHHS guidelines for the use of antiretroviral agents in HIV-1 adults and adolescents. Accessed August 10, 2007. URL: http://aidsinfo.nih.gov.
11. Blower S, Smith R, Okano J, et al. 2007. Evolving waves of single, dual and triple class resistance in San Francisco. 2007 HIV Resistance Workshop. Barbados, West Indies. June 12-16, 2007. Abstract # 38.
12. Broder S, Gallo RC. 1984. A pathogenic retrovirus (HTLV-III) linked to AIDS. N Eng J Med, 311:1292-7.
13. [CDC] Centers for Disease Control and Prevention. 2005. HIV/AIDS Surveillance Report, 2005. Vol 17, Rev ed. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention: 1-54. URL: http://cdc.gov/hiv/topics/surveillance/resources/reports/.
14. Chan DC, Kim PS. 1998. HIV entry and its inhibition. Cell, 93:681-4.
15. Chander G, Himelhoch S, Moore RD. 2006. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs, 66:769-89.
16. Chapman T, McGavin J, Noble S. 2003. Tenofovir disoproxil fumarate. Drugs, 63:1597-608.
17. Charpentier C, Nora T, Tenallion O, et al. 2006. Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J Virol, 80:2472-82.
18. Chun TW, Carruth L, Finzi D, et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature, 387:183-8.
19. Chun TW, Finzi D, Margolick J, et al. 1995. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med, 1:1284-90.
20. Coombs RW, Collier AC, Allain JP, et al. 1989. Plasma viremia in human immunodeficiency virus infection. N Engl J Med, 321:1626-31.
21. Csajka C, Marzolini C, Fattinger K, et al. 2003. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther, 73:20-30.
22. Dando TM, Wagstaff AJ. 2004. Emtricitabine/tenofovir disoproxil fumarate. Drugs, 64:2075-82.
23. Egger M, May M, Chene G, et al. 2002. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet, 360:119-29.
24. Emtriva® Package Insert. 2006. Gilead Sciences, Inc., Foster City, California. December 2006.
25. Enejosa J, Chen SS, Cheng MK. 2006. Efficacy and safety of tenofovir DF (TDF) containing versus thymidine analog-containing regimens in antiretroviral naïve HIV-1 infected women. HIV DART 2006: Frontiers in Drug Development for Antiretroviral Therapies, December 10-14, 2006, Cancun, Mexico.
26. Eron JJ, Feinberg J, Kessler HA, et al. 2004. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral naïve HIV-positive patients: a 48-week randomized clinical trial. J Infec Dis, 189:265-72.
27. Finzi D, Blankson J, Siliciano JD, et al. 1999. Latent infection of CD4+ T-cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective therapy. Nature Med, 5:512-7.
28. Fleming T, ed. 2007. Red Book 2007: Pharmacy's Fundamental Reference. Tampa, FL: Thomson Publishing Group.
29. Folks T, Kelly J, Benn S, et al. 1986. Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol, 136:4049-53.
30. Frampton JE, Croom KF. 2006. Efavirenz/emtricitabine/tenofovir disoproxil fumarate triple combination tablet. Drugs, 66:1501-12.
31. Frampton JE, Perry CM. 2005. Emtricitabine: a review of its use in the management of HIV infection. Drugs, 65:1427-48.
32. Gallant JE, DeJesus E, Arribas JR, et al. 2006. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med, 354:251-60.
33. Garcia-Blanco MA, Cullen BR. 1991. Molecular basis of latency in pathogenic human viruses. Science, 254:815-20.
34. Gatanaga H, Hayashida T, Tsuchiya K, et al. 2007. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis, 45:1230-7.
35. Glaros AG, Glass EG. 1993. Temporomandibular disorders. In Gatchel RJ, Blanchard EB (Eds). Psychophysiological disorders: Research and clinical applications. Washington, DC: American Psychological Association. pp. 299-356.
36. Goedken AM, Herman RA. 2005. Once daily abacavir in place of twice-daily administration. Ann Pharmacother, 39:1302-8.
37. Gulick RM, Mellors JW, Havlir D, et al. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Eng J Med, 337:734-9.
38. Haas DW, Ribaudo HJ, Kim RB, et al. 2004. Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trial group study. AIDS, 18:2391-400.
39. Hammer SM, Saag MS, Schechter M, et al. 2006. Treatment for HIV infection: 2006 recommendations of the International AIDS Society - USA Panel. J Amer Med Assoc, 296:827-43.
40. Hammer SM, Squires KE, Hughes MD, et al. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Eng J Med, 337:725-33.
41. Haynes RB, Taylor DW, Sackett DL. 1979. Compliance in health care. Baltimore: Johns Hopkins University Press.
42. Heeswijk RP, Veldkamp AI, Mulder JW, et al. 2000. The steady-state pharmacokinetics of nevirapine during once and twice daily dosing in HIV-1 infected individuals. AIDS, 14:77-82.
43. Ho DD, Moudgil T, Alam M. 1989. Quantitation of human immunodeficiency virus type-1 in the blood of infected persons. N Engl J Med, 321:1621-5.
44. Izzedine H, Isnard-Bagnis C, Hulot J, et al. 2004. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS, 18:10067-78.
45. Izzedine H, Hulot J, Vittecoq D, et al. 2005. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral naive HIV-1 infected patients. Data from a double-blind randomized active-controlled mutlicentre study. Nephrol Dial Transplant, 743-6.
46. Johnson VA, Brun-Vezinet F, Clotet B, et al. 2007. Update of the drug resistance mutations HIV-1: 2007. Top HIV Med, 15:119-25.
47. Kappelhoff BS, van Leth F, Robinson PA, et al. 2005. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther, 10:489-98.
48. Karras A, Lafaurie M, Furco A, et al. 2003. Tenofovir-related nephrotoxicity in human immunodeficiency virus infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Inf Dis, 36:1070-3.
49. Lamba V, Lamba J, Yasuda K, et al. 2003. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR expression. J Pharmacol Exper Ther, 307:906-22.
50. Levy JA. 1993. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev, 57:183-289.
51. Levy JA. 2007. HIV and the Pathogenesis of AIDS. 3rd ed. Washington, D.C.: ASM Press.
52. Little SJ, Smith DM. 2005. HIV treatment decisions and transmitted drug resistance. Clin Infect Dis, 41:233-5.
53. Lyseng-Williamson KA, Reynolds NA, Plosker GL. 2005. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs, 65:413-32.
54. McColl DJ, Margot NA, Chuang S, et al. 2006. Study 934: lower rates of resistance development associated with tenofovir DF and emtricitabine plus efavirenz by week 96. 8th International Congress on Drug Therapy in HIV Infection. Glascow, UK. November 12-16, 2006. p.199.
55. McDonald HP, Garg AX, Haynes RB. 2002. Interventions to enhance patient adherence to medication prescriptions: scientific review. J Amer Med Assoc, 288:2868-79.
56. Maglione M, Goetz M, Wang Z, et al. 2007. Antiretroviral (ARV) Drug Resistance in the Developing World. Evid Rep Technol Assess, 156:1-74.
57. Markowitz M, Nguyen B-Y, Gotuzzo F. 2006. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naive HIV-1 infected patients. Program and abstracts of the XVI International AIDS Conference. August 13-18, 2006. Toronto, Canada. Abstract THLB0214.
58. Mathias AA, Hinkle J, Menning M, et al. 2007. Bioequivalence of efavirenz/emtricitabine/tenofovir DF single tablet regimen. J Acquir Immune Defic Syndr, 46:167-73.
59. Montfore A, Sabin CA, Phillips A, et al. 2005. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med, 165:416-23.
60. Motsinger AA, Ritchie MD, Shafer RW, et al. 2006. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult clinical trials group study. Pharmacogenet Genomics, 16:837-45.
61. Moyle GJ, DeJesus E, Cahn P, et al. 2005. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naïve HIV-infected adults. J Acquir Immune Def Syndr, 38:417-25.
62. Murri R, Ammasari A, Trotta MP, et al. 2004. Patient reported and physician estimated adherence to HAART. J Gen Intern Med, 19:1104-10.
63. Nabel G, Baltimore D. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature, 326:711-3.
64. Palella FJ, Delaney KM, Moorman AC. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med, 338:853-60.
65. Paterson DL, Swindells S, Mohr J, et al. 2000. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med, 133:21-30.
66. Perelson AS, Neumann AU, Markowitz M, et al. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science, 271:1582-6.
67. Peyriere H, Reynes J, Rouanet I, et al. 2004. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr, 35:269-73.
68. Pfister M, Labbe L, Hammer SM, et al. 2003. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir. Antimicrob Agents Chemother, 47:130-7.
69. Pozniak AL, Gallant JE, DeJesus E, et al. 2006. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/ lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr, 43:535-40.
70. Rahim S, Fredrick LM, da Silva B, et al. 2007. Geographical and temporal trends of transmitted HIV-1 resistance amount antiretroviral naïve subjects screening for clinical trials. 2007 International HIV Drug Resistance Workshop. Barbados, West Indies. June 12-16, 2007. Abstract #49.
71. Ray AS, Cihlar T, Robinson KL, et al. 2006. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother, 3297-304.
72. Ribaudo HJ, Haas DW, Tierney C, et al. 2006. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an AIDS clinical trial group study. Clin Infect Dis, 42:401-7.
73. Riddler SA, Haubrich R, DiRienzo G, et al. 2006. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142. Program and abstracts of the XVI International AIDS Conference. August 13-18, 2006. Toronto, Canada. Abstract THLB0204.
74. Robbins BL, Srinivas RV, Kim C, et al. 1998. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxyp ropyl)adenine (PMPA), Bis(isopropylmoxymethylcarbonyl)PMPA. Antimicrob Agent Chemother, 42:612-7.
75. Rollot F, Nazal E, Chauvelot-Moachon L, et al. 2003. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with aquired immune deficiency syndrome: the role of lopinavir-ritonavirdidanosine. 37:e174-6.
76. Ross LL, Williams V, Wine B, et al. 2007. Changes in the regional prevalence of HIV-1 drug resistance-associated mutations and in the prevalence of non-clade B sub types in antiretroviral therapy-naïve HIV-infected patients in the United States from 2000-2006. 2007 International HIV Drug Resistance Workshop. Barbados, West Indies. June 12-16, 2007. Abstract #47.
77. Rueda S, Park-Wyllie LY, Bayoumi AM, et al. 2007. tient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database of Systematic Reviews, 2.
78. Sarkar I, Hauber I, Hauber J, Buchholz F. 2007. HIV-1 proviral DNA excision using an evolved recombinase. Science, 16:1912-5.
79. Sambamoorthi U, Walkup J, Olfson M, et al. 2000. Antidepressant treatment and health services utilization among HIV-infected symptoms Medicaid patients diagnosed with depression. J Gen Intern Med, 15:311-20.
80. Simen BB. 2007. Ultradeep versus standard sequencing in subset of FIRST trial participants. 2007 International HIV Drug Resistance Workshop. Barbados, West Indies. June 12-16, 2007. Abstract 134.
81. Staszewski S, Pozniak AL, Gallant J, et al. 2006. Renal safety profile of tenofovir DF (TDF)-containing compared to non-TDF-containing regimens in antiretroviral naïve patients with mild renal impairment or hypertension and/or diabetes mellitus. 8th International Congress on Drug Therapy in HIV Infection. November 12-14, 2006. Glasgow, Scotland, UK. Abstract P157.
82. Sustiva® Package Insert. 2007. Bristol-MyersSquibb Company, Princeton, New Jersey. January 2007. Sustiva (efavirenz) capsules and tablets prescribing information [online]. Accessed August 10, 2007. URL: www.bms.com.
83. Tirelli U, Vaccher E, Carbone A, et al. 1985. HTLV-III infection among 315 intravenous drug abusers: seroepidemiological, clinical and pathological findings. AIDS Res, 2:325-34.
84. Truvada® Package Insert. 2006. Gilead Sciences, Inc. Foster City, California, US. March 2006.
85. Turner BJ, Laine C, Cosler L, et al. 2003. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med, 18:248-57.
86. Van Dulmen S, Sluijs E, van Dijk L, et al. 2007. Patient adherence to medical treatment: A review of reviews. BMC Health Services Research, 7:55.
87. Vervoort SC, Borleffs JM, Hoepelman JC, et al. 2006. Adherence in antiretroviral therapy: A review of qualitative studies. AIDS, 21:271-81.
88. Viread® Package Insert. 2007. Gilead Sciences, Inc., Foster City, California. May 2007.
89. Wei X, Ghosh SK, Taylor ME, et al. 1995. Viral dynamics in human immunodeficiency virus type-1 infection. Nature, 373:117-22.
90. Wensing AM, Vercauteren J, van de Vijver DA. 2006. Transmission of HIV drug resistance in Europe. Program and abstracts of the XVI International AIDS Conference. August 13-18, 2006. Toronto, Canada. Abstract TUAB0101.
91. Yerly S, von Wyl V, Ledergerber B, et al. 2007. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS, 21:2223-9.
92. Young SD, Britcher SF, Tran LO, et al. 1995. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother, 39:2602-5.
93. Yun LW, Maravi M, Kobayashi JS, et al. 2005. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immun Defic Syndr, 38:432-8.